Regen BioPharma (OTCMKTS:RGBP) versus LianBio (NASDAQ:LIAN) Financial Comparison

Regen BioPharma (OTCMKTS:RGBP) and LianBio (NASDAQ:LIAN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Earnings and Valuation

This table compares Regen BioPharma and LianBio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regen BioPharma	N/A	N/A	N/A	-0.01	-5.59
LianBio	N/A	N/A	-$110.29 million	($0.81)	-0.36

Regen BioPharma is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Regen BioPharma and LianBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regen BioPharma	0	0	0	0	0.00
LianBio	1	1	0	0	1.50

LianBio has a consensus target price of $3.50, indicating a potential upside of 1,115.53%. Given LianBio’s stronger consensus rating and higher probable upside, analysts clearly believe LianBio is more favorable than Regen BioPharma.

Profitability

This table compares Regen BioPharma and LianBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regen BioPharma	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

Institutional and Insider Ownership

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

LianBio beats Regen BioPharma on 5 of the 8 factors compared between the two stocks.

About Regen BioPharma

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It engages in identifying small molecules that inhibit or express NR2F6 leading to immune cell activation for oncology applications, and immune cell suppression for autoimmune disease. The company is involved in the development of its products, and therapies, including HemaXellarate, a cellular therapeutic product of autologous stromal vascular fraction derived from adipose tissue; dCellVax, an autologous dendritic cell which is treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax which is treated with siRNA to inhibit NR2F6 and the cells re-infused to the patient; DiffronC, uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuroCAR comprising of CAR-T cells which is treated with an shRNA targeting the gene NR2F6. The company was incorporated in 2012 and is based in La Mesa, California.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.